Respiratory Involvement in Patients with Neuromuscular Diseases: A Narrative Review

Athanasios Voulgaris,1,2 Maria Antoniadou,1,3 Michalis Agrafiotis1,3 and Paschalis Steiropoulos1,2

1MSc Program in Sleep Medicine, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
2Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
3Department of Pneumonology, General Hospital “G. Papanikolaou”, Thessaloniki, Greece

Correspondence should be addressed to Paschalis Steiropoulos; steiropoulos@yahoo.com

Received 29 August 2018; Revised 8 April 2019; Accepted 20 November 2019

Academic Editor: Roberto Walter Dal Negro

Respiratory muscle weakness is a major cause of morbidity and mortality in patients with neuromuscular diseases (NMDs). Respiratory involvement in NMDs can manifest broadly, ranging from milder insufficiency that may affect only sleep initially to severe insufficiency that can be life threatening. Patients with neuromuscular diseases exhibit very often sleep-disordered breathing, which is frequently overlooked until symptoms become more severe leading to irreversible respiratory failure necessitating noninvasive ventilation (NIV) or even tracheostomy. Close monitoring of respiratory function and sleep evaluation is currently the standard of care. Early recognition of sleep disturbances and initiation of NIV can improve the quality of life and prolong survival. This review discusses the respiratory impairment during sleep in patients with NMDs, the diagnostic tools available for early recognition of sleep-disordered breathing and the therapeutic options available for overall respiratory management of patients with NMDs.

1. Introduction

Neuromuscular diseases (NMDs) encompass a diverse group of diseases which may affect the upper motor neurons, lower motor neurons, peripheral nerves, the neuromuscular junction, and muscles. Although this definition may include a large variety of disorders, the term “neuromuscular” is reserved for inherited or acquired diseases predominately manifesting with motor dysfunction. From the pulmonologist’s perspective all NMDs present with a common trait: impairment of ventilatory function. This impairment is caused by either compromised airway patency and protective reflexes and/or by reduced respiratory pump efficiency. These pathophysiological events result in sleep-disordered breathing, followed by diurnal hypoventilation at later disease stages. In addition, patients with NMDs are prone to developing various other respiratory complications such as infections, atelectasis, and aspiration syndromes [1, 2]. The introduction of ventilatory support in the early stages of symptomatic sleep hypoventilation, especially in the form of noninvasive ventilation (NIV), as well as various other advances in respiratory care have contributed significantly to the improvement of survival and the quality of life of patients with NMDs [3–6].

NMDs can be hereditary or acquired, slowly or rapidly progressive [7, 8]. Inherited NMDs are not uncommon, with an estimated prevalence exceeding 1 in 3000 among newborns [9]. The prevalence of the majority of NMDs generally ranges between 1 and 10/100000 population; however some disorders are much more common e.g. postpolio syndrome and Charcot-Marie-Tooth disease with a prevalence greater than 10/100000, whereas others are quite rare, e.g. Lambert-Eaton myasthenic syndrome and congenital muscular dystrophies with a prevalence of less than 1/100000 [10]. In a European survey, among patients treated with domiciliary mechanical ventilation, neuromuscular patients were most likely to receive prolonged (>6 years) ventilatory support and to undergo tracheostomy procedures [11].

NMDs cause respiratory disease mainly by causing respiratory muscle dysfunction. Respiratory insufficiency had been the main cause of morbidity and mortality in patients...
with NMDs until recent respiratory care became available [12, 13]. Respiratory complications and failure will eventually develop in the majority of the patients with NMDs although the age of onset might vary depending on the rate of disease progression. For example, most of the children with spinal muscular atrophy (SMA) type 1 will develop respiratory failure and die before the age of 3 years without adequate respiratory management, while respiratory failure will present later in childhood in only 40% of patients with SMA type 2 [14, 15]. In patients with Duchenne muscular dystrophy (DMD), respiratory failure commonly appears after the loss of ambulation [16]. Conversely, respiratory failure can precede non respiratory muscle weakness, in patients with Pompe’s disease and amyotrophic lateral sclerosis [17, 18].

NMDs can also present with various non respiratory manifestations. DMD may cause left ventricular insufficiency and conduction abnormalities [19]. Patients with NMDs may also manifest bony deformities such as chest wall and spine abnormalities. In DMD, scoliosis commonly presents during the second decade of life, after patients become wheelchair-bound, as a result of paravertebral muscle atonia [20]. Conversely, and unless ventilatory support is provided, patients with SMA types 1 and 2 develop bell-shaped chest deformity and pectoral excavatum attributed to the preferential involvement of intercostal muscles and the relative sparing of the diaphragm [21]. Patients with myotonic dystrophy commonly exhibit a mild cognitive impairment and a narcolepsy-like clinical phenotype, associated with excessive daytime sleepiness without adequate management for SDB [22, 23].

2. Respiratory Function in Patients with Neuromuscular Diseases

From a practical point of view, the respiratory muscles can be grouped into inspiratory (main and accessory), expiratory, and the upper airway muscles. Dysfunction of these groups can manifest as three different types of failure: (1) respiratory pump failure (inspiratory muscles’ dysfunction) (2) upper airway failure, and swallowing dysfunction (upper airway muscles’ dysfunction) and (3) cough failure (inspiratory, expiratory, and upper airway muscles dysfunction) [1, 13].

The respiratory pump is responsible for moving the air in and out of the lungs. The respiratory pump fails when it operates against an increased workload or when the respiratory muscles fail to generate enough force. Both of these circumstances predispose to respiratory muscle fatigue, which is defined as the inability to sustain a contractile force against a constant workload [24]. As fatigue increases the patient develops a rapid shallow breathing pattern, which is not fatigue-specific, but rather a reflex response to increased work of breathing [25].

In patients with NMDs the contractile function of the inspiratory and expiratory muscles is impaired. Moreover, chest wall compliance is decreased as a result of scoliosis and stiffening of the thoracic cage tendons and ligaments, while recurrent aspirations, microatelectasis, and pulmonary congestion due to cardiac disease are responsible for a decrease in lung compliance [26]. In addition, the upper airway collapsibility and hypotonia lead to increased resistance to airflow, which also contributes to the increased workload of the failing respiratory pump [27]. Although the initial physiologic response to these events is an increase in respiratory drive, this mechanism is eventually insufficient to maintain alveolar ventilation and hypoventilation finally ensues [28, 29]. Moreover, upper airway muscle failure also accounts for swallowing dysfunction and impaired airway protection, leading to recurrent episodes of aspiration and pneumonia [13].

Normal cough consists of an initial inspiratory phase to reach a lung volume equal to 85–90% of TLC; a compression phase characterized by rapid closure of the glottis for 0.2 seconds with simultaneous contraction of the expiratory muscles to create a pressure greater than 200 cm H2O; and an expulsion phase characterized by rapid opening of the glottis while the expiratory muscles continue to contract in order to produce an expiratory cough flow greater than 400 L/min [30]. High cough flows are essential for removing secretions and debris and clearing the airways. Therefore, impairment of either the inspiratory, expiratory or glottic muscles in patients with NMDs might compromise effective cough function leading to increased susceptibility to respiratory infections, atelectasis and respiratory failure [1, 31].

3. Respiratory Function during Sleep in Patients with Neuromuscular Diseases

Normal sleep is characterized by a decrease in alveolar ventilation by 1–2 L/min mainly caused by a decrease in tidal volume, while the pattern of breathing becomes shallow and irregular [32]. As a result, PCO2 increases and O2 decreases by 2–8 mm Hg each, while the ventilatory response to hypoxemia and hypercapnia is attenuated [33, 34]. These changes become more pronounced during deep sleep and especially during phasic REM sleep [32]. There are several reasons accounting for these physiologic events, including the reduced lung volume in the supine position, the withdrawal of the wakefulness drive to breathe and the reduced chemosensitivity of respiratory center control [35]. In addition, the tone of the intercostal muscles decreases during sleep [36], while the tone of the diaphragm decreases during NREM but is maintained during REM sleep; as a result, normal ventilation during REM sleep becomes totally dependent on the diaphragmatic function [37]. Finally, the activity of the pharyngeal dilator muscles - particularly of the genioglossus—decreases gradually during sleep resulting in increased upper airway resistance which becomes maximal during REM sleep [38].

These events are more pronounced in patients with NMDs as a result of respiratory and upper airway muscle weakness. The most frequent breathing disorder in NMDs is hypoventilation presenting at first during REM sleep and then occurring at all sleep stages and finally when the patient is awake [39, 40]. Symptoms suggestive of nocturnal hypventilation are sudden arousals, morning headache, daytime sleepiness, and fatigue [41].

The most common respiratory event during sleep in NMDs is central hypopnea [42–45]. Central hypopneas are most commonly observed during phasic REM sleep, as a result of the
decreased tone of the intercostal and accessory muscles combined with inadequate function of the diaphragm [42, 44–46]. Obstructive events are also observed in patients with NMDs, especially in DMD and acid maltase deficiency. In these disorders, sleep disordered breathing follows a bimodal distribution with obstructive events occurring early in the course of the disease while frank hypoventilation prevails at later years [43, 47]. In addition, obstructive events do not appear to be more likely in bulbar ALS patients, although the evidence here is equivocal [48, 49]. Some studies suggest that obstructive events are more likely in patients with a higher body mass index (BMI), in those with anatomic abnormalities such as macroglossia, and in those with increased upper airway resistance during REM sleep [42, 43, 50]. Furthermore, Cheyne-Stokes breathing and other central sleep apnea syndromes in association with cardiomyopathy and unstable control of breathing have also been reported [51, 52]. During sleep, patients with NMDs also exhibit hypoxemia which is related to the presence of hypoventilation, apneas and hypopneas, and ventilation-perfusion mismatch due to atelectasis occurring in the supine position [53].

4. Evaluation of Respiratory Function and Cough in Patients with Neuromuscular Diseases

Respiratory assessment in patients with NMDs includes evaluation of respiratory muscle strength, gas exchange, and cough efficiency. Spirometry, arterial blood gas, mouth and nasal pressures are among the most widely used techniques.

In NMDs impairment of respiratory muscle contractile function leads to respiratory pump failure, characterized by decreases in vital capacity (VC), total lung capacity (TLC) and functional residual capacity (FRC) [54]. This reduction in VC is further augmented in the supine position and a drop of greater than 25% is considered 90% sensitive and 79% specific for the diagnosis of diaphragmatic weakness [55]. Interestingly, a decrease in VC can be observed earlier in the course of the disease as compared to TLC, due to the increased residual volume (RV) observed in patients with expiratory muscle weakness [56]. However, although VC is considered a robust index for the respiratory evaluation of patients with NMDs, it can be fairly insensitive in early disease stages. In a study involving patients with various types of NMDs, an inspiratory VC of less than 60% predicted the presence of sleep apnea syndrome and a VC of less than 40% was associated with sleep hypoventilation with a sensitivity of 91% and 94% and a specificity of 89% and 79% respectively; patients with a VC of less than 25% suffered from daytime ventilatory failure [39]. In a cohort involving more than 1000 patients with ALS, forced vital capacity (FVC) less than 75% was associated with a median survival of 2.91 years as opposed to 4.08 years for patients with FVC of greater than 75% [57]. In another study, a supine FVC of less than 80% was 94.6% sensitive in predicting death or tracheostomy within the first year in a group of patients with ALS [58]. In patients with DMD, VC increases until the age of 10–12 years, when it reaches a plateau, followed by a decline which can be as high as 10.7% per year [59]. Loss of ambulation and establishment of scoliosis is associated with an accelerated decline in lung function in DMD patients and a VC of less than 1L predicts a 5-year survival rate of 8% without adequate noninvasive respiratory support [8, 60, 61]. Moreover, an inspiratory VC of less than 1.1L could reliably identify patients at high risk for severe chest infections in a retrospective study involving children and adolescents with various NMDs [62].

An increased PCO₂ value in arterial blood gas indicates the presence of diurnal respiratory pump failure. In addition, an increased alveolar-arterial difference should point towards a concurrent parenchymal lung disease. Of note, PCO₂ commonly appears reduced at initial disease stages but increases later when respiratory muscle impairment has progressed significantly [63]. Importantly, either diurnal hypercapnia or an increased bicarbonate or base excess (BE) level might indicate coexistent nocturnal hypoventilation. In a study of patients with DMD, values of PCO₂ >45 mmHg and BE >4 mmol/L predicted nocturnal hypoventilation with a sensitivity of 99% and 55% and a specificity of 75% and 100% respectively [64].

Cough efficiency is assessed by measuring cough flow variables, of which the most important are peak expiratory cough flow (PECF) and cough volume acceleration (CVA). Either a customary handheld peak flow meter, which is used for patients with asthma, or an office spirometer, can be used for cough flow measurements; however it should be noted that significant differences between pneumotachograph- and peak flow meter-based assessments have been reported [65]. Nevertheless, an inefficient cough is characterized by a lower peak inspiratory cough flow, a longer compression phase and a lower PECF [66].

PECF is the highest cough flow obtained after instructing the patient to take a deep breath and cough forcibly. For adults and older children, a PECF of less than 160 L/min is associated with ineffective secretion clearance and tracheostomy decannulation failure [67]. Moreover, a PECF less than 270 L/min is associated with higher risk for acute respiratory failure and higher respiratory morbidity during the course of a trivial respiratory tract infection [68–70]. Most authorities would consider a PECF less than 270 L/min as an indication for commencement of cough augmentation strategies [71, 72].

CVA is derived by dividing PECF by the time required to reach its value (peak expiratory flow rise time, PEFRT). In a prospective study involving stable ALS patients, a CVA of less than 28.9 L/sec² was slightly more reliable than PECF in predicting ineffective cough during a respiratory tract infection [69]. In addition, when compared to PECF and PEFRT, CVA was the most reliable predictor of aspiration in patients with ALS [66]. In another study, the strength of cough in patients with ALS correlated with the ability to produce transient cough spikes during a maximal flow-volume maneuver; the absence of these spikes also correlated with increased mortality [73, 74].

Maximum insufflation capacity (MIC) and lung insufflation capacity are also important variables in the assessment of cough function. MIC is defined as the maximum volume of air that can be held in the lungs while the glottis is closed and is obtained by instructing the patient to stack several volumes
of air after taking a deep breath. Air stacking can be performed with the use of a volume ventilator or a resuscitation bag with an one way valve, or with the technique of glossohyrgeal breathing [75]. When the glottic function is not intact, the same effect can be obtained via the use of a manual resuscitator with the expiratory port blocked, or a volume ventilator set to deliver volumes close to the subject's inspiratory capacity or a mechanical insufflator-exsufflator device (MI-E); in that instance the term lung insufflation insufflation is preferred (LIC) [76]. LIC can be measured with a simple spirometer and the greater the difference between VC and LIC, the higher the PECP that will be achieved when the patient coughs from maximum insufflation [72, 76, 77]. Measurements of maximal static mouth pressures are among the most common methods used to assess inspiratory and expiratory muscle strength in daily clinical practice. They are measured via a mouthpiece, which is connected to a manometer. One limitation of the static mouth pressures is that they cannot be measured reliably in patients with facial muscle weakness [78]. Maximum inspiratory pressure (MIP) is the average pressure sustained over 1 sec when the subject takes a deep breath against a blocked mouthpiece from the RV (Mueller maneuver). MIP correlates well with VC in children and adults with various types of NMDs [39, 79–81]. When evaluated in a mixed population of children and adolescents with NMDs, a MIP less than −46 cm H2O predicted the presence of sleep apnea and a MIP less than −40 cm H2O was associated with sleep hypventilation with a sensitivity of 82 and 95% and specificity of 89% and 65%, respectively [39]. Unlike VC, MIP is neither related to the number of chest infections nor the total days of antibiotic therapy during the preceding year [62]. Maximal expiratory pressure (MEP) is the average pressure sustained over 1 sec when the subject blows against a blocked mouthpiece from TLC (Valsava maneuver). A MEP greater than +60 H2O is required to produce an efficient cough, while a MEP of less than +45 H2O suggests impaired expiratory muscle function and decreased ability to cough [82]. In a study involving children and adolescents with DMD, MEP correlated with VC, but its rate of decline during the course of the disease was higher as compared to MIP and VC [81]. MEP has also been shown to correlate with the number of infections and the number of days on antibiotic therapy in the preceding year, although the correlation is weaker than for VC and PECP [62]. Nasal pressures are measured via a plug wedged into the nostril and connected to a manometer, while the subject per- forms a quick sniff, i.e., a sharp voluntary inspiratory maneuver through the nostril (sniff nasal inspiratory pressure, SNIP). This maneuver is performed from FRC and although it might be easier to perform and more suitable for patients with facial muscle weakness, more than 10 attempts are often required before a plateau is reached [78, 83]. SNIP has a strong correlation with PCO2 in nonbulbar patients with ALS and a SNIP of less than −40 cm H2O was the most reliable noninvasive predictor of hypercapnic respiratory failure in nonbulbar ALS patients with a sensitivity of 85% and a specificity of 81% [63, 84]. In a prospective study of 98 patients with ALS, a SNIP < −40 cm H2O was significantly correlated with the severity of nocturnal hypoxemia, while no such association was established for MIP and VC; in the same study, a SNIP < −40 cm H2O was associated with a median survival of 6 months [85]. In a more recent study of patients with ALS, a SNIP of less than −34 cm H2O could predict death or tracheostomy within one year with a sensitivity of 75% and a specificity of 72% [86]. Another study evaluated the evolution of MIP, SNIP, and VC in patients with DMD and Becker muscular dystrophy (BMD), between 5 and 20 years old. In patients with DMD, MIP remained stable, while VC and SNIP decreased consistently after an initial increase; however, SNIP showed an earlier decline than VC (at 10.5 years versus 12.5 years, respectively) [87].

5. Evaluation of Sleep-Disordered Breathing in Patients with Neuromuscular Diseases

Polysomnography (PSG) complemented by capnography is the gold standard method for the assessment of sleep-disordered breathing in patients with neuromuscular diseases, and overnight PSG should be applied when available [14, 16, 20, 88]. The American Thoracic Society recommends annual evaluation of sleep disordered breathing in children with DMD, ideally using PSG with simultaneous measurement of CO2 [16, 20]. However, in younger children with uncertain course of the disease or with rapid clinical deterioration or in patients with recurrent infections, sleep monitoring should be performed more frequently [16, 20, 88]. Nevertheless, and especially in cases where polysomnography is not available, other types of sleep studies such as cardiorespiratory polygraphy or pulse oximetry should be considered although these may not be sensitive enough to detect sleep-disordered breathing in NMDs [88, 89]. Indeed, although a "sagging" oximetry profile is a feature of sleep hypventilation in patients with NMDs, short or mild episodes or hypventilation might be missed by overnight pulse oximetry; however, some authorities assert that clinical significant hypventilation is unlikely in asymptomatic patients who do not desaturate below 95% [88, 90]. Nevertheless, according to several authors, a desaturation to a value <88% (or 90%) for 5 consecutive minutes or a desaturation to a value <90% for 10% (or 30%) of the total recording time might be indicators of sleep hypventilation in neuromuscular patients [90–93]. The addition of capnography might increase the diagnostic sensitivity of oximetry and the use of oxicapnometry could be considered as a more practical approach for neuromuscular patients when polysomnography is not available [88, 94–96]. According to the American Academy of Sleep Medicine scoring rules, sleep hypventilation in adults is defined as 1) an increase in PCO2 (arterial, transcutaneous or end-tidal) to a value >55 mmHg for ≥10 minutes or (2) an increase in PCO2 by >10 mmHg, to a value >50 mmHg for ≥10 minutes. In children, sleep hypventilation is scored when PCO2 exceeds 50 mmHg for >25% of total sleep time [97]. Some authors have employed alternative definitions of sleep hypventilation, including a peak transcutaneous PCO2 >49 mmHg [93] or a mean transcutaneous PCO2 >50 mmHg [3, 15]. However, because various definitions are used for sleep hypventilation [98], levels of CO2 approaching 50 mmHg during sleep are suggestive of nocturnal hypventilation and should indicate
institution of nocturnal NIV [6, 16, 20, 88]. Apart from hypoventilation, the detection of upper airway obstructive events before or after the initiation of NIV might also be of prognostic significance in certain diseases, e.g. ALS [99, 100]. As a rule, initiation of NIV should not be delayed when abnormal findings on oximetricography combined with morning signs of nocturnal hypoventilation are detected [88].

6. Respiratory Management of Patients with Neuromuscular Diseases

The aim of respiratory management of patients with NMDs is threefold: ventilatory support, cough augmentation, and lung volume recruitment. Ventilatory support assists the function of the feeble respiratory muscles and stabilizes gas exchange; cough augmentation improves cough flows and supports secretion clearance; and lung volume recruitment aims to avert functional decline as a result of atelectasis and chest wall contractures [76, 101].

Ventilatory support can be provided either via a noninvasive interface (e.g. nasal, oronasal mask or a mouthpiece) or invasively via a tracheostomy. Although, ventilatory support was initially applied in the form of negative pressure ventilation to treat patients with poliomyelitis in the 1950s, it is now most commonly administered in the form of positive pressure ventilation and is the treatment of choice for patients with NMDs and acute or chronic ventilatory failure [5, 6, 88, 91, 102].

The mechanisms which account for the beneficial effect of NIV on respiratory physiology of patients with NMDs remain unclear. Possible mechanisms include the unloading of the respiratory muscles, the resetting of the respiratory center and improvement in lung mechanics [103]. Nickol et al. suggested that the main benefit of NIV in restrictive lung diseases (kyphoscoliosis and neuromuscular diseases) is associated with the resetting of the chemoreceptors to a lower level of PCO₂, probably due to reduced renal retention of bicarbonates [104].

Many authorities suggest that NIV should be started in patients with symptoms of nocturnal hypoventilation (e.g. headache, fatigue, daytime sleepiness) plus abnormal findings in oximetry or capnometry (as discussed above). Other indications include a reduced VC (e.g. <50%), decreased respiratory muscle pressures (e.g. SNIP < 40 cm H₂O or MIP < 65 cm H₂O) or a daytime PCO₂ > 45 mmHg [16, 90–92, 105, 106].

It should be noted that tracheostomy ventilation used to be the standard treatment for patients with prolonged or total ventilator dependence and for those with impaired secretion clearance due to weak cough; however the combination of nasal or mouthpiece ventilation (MPV) with cough augmentation strategies has made this option obsolete for the majority of patients with NMDs, except for those with advanced bulbar disease [107–110].

NIV should be administered early during the course of the disease to treat patients with symptomatic sleep hypoventilation. In a randomized controlled trial, which compared NIV to supportive care in normocapnic patients with neuromuscular and chest wall disease and sleep hypoventilation, patients who did not receive NIV experienced faster deterioration, earlier establishment of daytime hypercapnia and more symptoms [3].

Several studies have suggested that NIV can prolong survival in patients with NMDs. A randomized controlled trial, in patients with ALS comparing NIV to supportive care, noted that NIV offered a survival advantage of 205 days, although this benefit was limited to nonbulbar patients. However, some indices of quality of life improved both in bulbar and nonbulbar patients [111]. In addition, a recent retrospective cohort study also observed an overall survival advantage of 15 months for both bulbar and nonbulbar patients with ALS who received treatment with NIV [112]. Simonds et al. conducted an observational study of 23 patients with DMD and diurnal and nocturnal ventilatory failure, who received NIV via nasal mask, and observed 1½ year survival rates of 73% and 85%, respectively [113]. A retrospective study in the total populations of DMD patients in Denmark reported a decrease in mortality from 4.7% to 2.6% per 100 years between 1977 and 2001, which was attributed to an increase in the use of mechanical ventilation from 0.9% to 43.4% during the same period [114].

Institution of NIV in patients with NMDs also improves daytime symptoms, quality of life and parameters of gas exchange. In a prospective observational study of ALS patients treated with NIV for 1 month, nocturnal oxygen and carbon dioxide improved in both bulbar and nonbulbar patients, while sleep quality and electroencephalographic indices of sleep fragmentation improved only in the nonbulbar subgroup [115]. An improvement in sleep and respiratory outcomes which persisted for 15 months was also noted in a retrospective study of bulbar and nonbulbar ALS patients treated with NIV [116]. In the study by Simonds et al., institution of NIV in patients with DMD was associated with an improvement in arterial blood gas values, which persisted throughout the treatment period, while the quality of life was equivalent to other groups of patients with nonprogressive respiratory disorders also treated with NIV [113]. Similarly, in patients with spinal muscular atrophy, NIV normalized sleep architecture and improved respiratory parameters, as well as symptoms of sleep-disordered breathing [117, 118]. In a study of 20 patients with various NMDs, application of NIV was associated with amelioration of the respiratory disturbance index, oxygen saturation, and transcutaneous PCO₂ as well as indices of daytime sleepiness, as Epworth Sleepiness Scale and Multiple Sleep Latency Test [119].

In the majority of the aforementioned studies [115–119] NIV titration was performed based on sleep oximetric or polysomnographic readings, while relatively low-span bilevel settings (<18 cm H₂O) were used. However, other authors have criticized this strategy as inadequate to effect complete respiratory muscle rest. These experts prefer the term "noninvasive ventilatory support (NVS)" to emphasize the role of this modality in substituting the respiratory muscles in the work of breathing [5, 6]. Their alternative approach does not employ sleep studies (e.g. polysomnography) for NIV initiation and titration. In fact, it consists of initially implementing NVS during sleep based on reduced supine VC and symptoms of sleep hypoventilation (fatigue, morning headaches, somnolence etc) using either tidal volumes at the range of 0.8–1.5 L in the volume-preset mode or high-span drive pressures...
(18–25 cm H$_2$O) in pressure-preset modes with a back-up respiratory rate commonly set to 12–14 breaths/minute; single limb circuits with true exhalation valves and nasal or oronasal or lipcover interfaces are commonly used. NVS is subsequently applied most of the day during wakefulness when the patient develops symptoms of breathlessness most commonly in volume-preset mode with an angled 15 mm mouthpiece used as interface. This set up allows the patient vary the inhaled tidal volume according to his needs and air-stack ad lib. Nasal masks can be alternatively used for patients with weak mouth muscles who are unable to grab the mouthpiece, while pressure-preset modes can be employed for patients who are unable to air-stack (e.g. infants). This approach is complemented by advanced secretion management strategies i.e., air-stacking and mechanical insufflation exsufflation (MI-E) and also incorporates specifically designed protocols to decannulate tracheostomized patients to 24-hour full ventilatory support [5,6]. According to these protocols, an assisted PECF > 160 L/min effected by a combination of MI-E and abdominal thrust is associated with a very high rate of tracheostomy decannulation success [110, 120].

The aim of the NVS strategy is to avert the use of invasive tubes (tracheostomies), improve survival rates and quality of life and reduce the number of hospital admissions [5, 6, 121]. Thus, in a study reporting on postpolio survivors, MPV was used for 1.028 patient-years (or 14.8 years per patient) for a total mortality of 1 per 60.5 patient-years [122]. In addition, in a study reporting on postpolio survivors, MPV was associated with a significant reduction in total admissions of 6 years, the prescription of lung volume recruitment decreased the rate of VC decline by 4.5% predicted/year to 0.5% predicted/year [128]. McKim et al. also reported retrospectively an 89% decrease in VC decline over a period of 78 months follow-up in 22 DMD patients who were prescribed lung volume recruitment sessions [130]. In another retrospective study on a mixed population of 21 patients with NMDs, the regular use of the MI-E device resulted in improvement in VC by 28% during the first year and stabilization during the second year [131].

In the case of acute respiratory failure (ARF) in patients with NMD, NIV, and aggressive secretion management with MI-E should be introduced. Importantly, NIV should be considered in patients with NMDs who present with an acute illness and exhibit tachypnea (respiratory rate >20/min), even if hypercapnia is absent, especially in those with a known VC < 1L [132, 133]. Adequate hydration should be ensured and the clinician should have a low threshold for administering antibiotics, particularly when there is high probability of an underlying chest infection [134]. The role of NIV combined with MI-E has been investigated in a prospective non-controlled study involving 16 children with NMDs and acute respiratory failure treated in a pediatric intensive care unit [135]. Hypercapnic respiratory failure was present in 15 cases (mean PaCO$_2$, 73.2 mmHg), whereas one had experienced hypoxemic ARF. NIV and MI-E were successfully delivered in 12 cases (75%) with a significant drop in PaCO$_2$ levels (>20 mmHg). Interestingly, all patients, including those who were invasively ventilated after intubation, were discharged from the hospital without the need for tracheostomy [135]. Nevertheless, failure of NIV and secretion management strategies (e.g. in the case of severe upper airway obstruction, cranio-facial abnormalities, or coma) should not delay early initiation of invasive ventilation.

7. Conclusions

Patients with neuromuscular diseases are at high risk for respiratory complications during the course of their disease. Early recognition of respiratory impairment is vital and a
multidisciplinary approach should be adopted in order to provide the best optimal treatment. Noninvasive positive pressure ventilation and advanced cough management strategies are currently the standard of care in neuromuscular diseases as they improve survival, sleep, and quality of life.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] J. O. Benditt, "The neuromuscular respiratory system: physiology, pathophysiology, and a respiratory care approach to patients," *Respiratory Care*, vol. 51, no. 8, pp. 829–837, 2006, Discussion 837-839.

[2] A. K. Simonds, "NIV and neuromuscular disease," *Noninvasive Ventilation*, vol. 41, pp. 224–239, European Respiratory Society, 2008.

[3] S. Ward, M. Chatwin, S. Heather, and A. K. Simonds, “Randomised controlled trial of noninvasive ventilation (NIV) for nocturnal hypventilation in neuromuscular and chest wall disease patients with daytime normocapnia,” *Thorax*, vol. 60, no. 12, pp. 1019–1024, 2005.

[4] L. F. Wolfe, N. C. Joyce, C. M. McDonald, J. O. Benditt, and J. Finder, "Management of pulmonary complications in neuromuscular disease," *Physical Medicine and Rehabilitation Clinics of North America*, vol. 23, no. 4, pp. 829–853, 2012.

[5] J. R. Bach, "Noninvasive positive pressure ventilatory support begins during sleep," *Sleep Medicine Clinics*, vol. 12, no. 4, pp. 607–615, 2017.

[6] J. R. Bach, "Noninvasive respiratory management of patients with neuromuscular disease," *Annals of Rehabilitation Medicine*, vol. 41, no. 4, pp. 519–538, 2017.

[7] C. M. McDonald, "Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases," *Physical Medicine and Rehabilitation Clinics of North America*, vol. 23, no. 3, pp. 495–563, 2012.

[8] N. Ambrosino, N. Carpenè, and M. Gherardi, "Chronic respiratory care for neuromuscular diseases in adults," *European Respiratory Journal*, vol. 34, no. 2, pp. 444–451, 2009.

[9] A. E. Emery, "Population frequencies of inherited neuromuscular diseases—a world survey," *Neuromuscular Diseases*, vol. 1, no. 1, pp. 19–29, 1991.

[10] J. C. Deenen, C. G. Horlings, J. J. Verschuuren, and A. L. Verbeek, B. G. Van Engelen, "The epidemiology of neuromuscular diseases: a comprehensive overview of the literature," *Journal of Neuromuscular Diseases*, vol. 2, no. 1, pp. 73–85, 2015.

[11] S. J. Lloyd-Owen, G. C. Donaldson, N. Ambrosino et al., “Patterns of home mechanical ventilation use in Europe: results from the Eureauo survey," *European Respiratory Journal*, vol. 25, no. 6, pp. 1025–1031, 2005.

[12] R. S. Howard, C. M. Wiles, N. P. Hirsch, and G. T. Spencer, “Respiratory involvement in primary muscle disorders: assessment and management,” *QJM: An International Journal of Medicine*, vol. 86, no. 3, pp. 175–189, 1993.

[13] C. Perrin, J. N. Unterborn, C. D. Ambrosio, and N. S. Hill, “Pulmonary complications of chronic neuromuscular diseases and their management,” *Muscle & Nerve*, vol. 29, no. 1, pp. 5–27, 2004.

[14] C. H. Wang, R. S. Finkel, E. S. Bertini et al., “Consensus statement for standard of care in spinal muscular atrophy," *Journal of Child Neurology*, vol. 22, no. 8, pp. 1027–1049, 2007.

[15] A. K. Simonds, "Chronic hypoventilation and its management," *European Respiratory Review*, vol. 22, no. 129, pp. 325–332, 2013.

[16] J. D. Finder, D. Birknkrant, J. Carl et al., “Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement," *American Journal of Respiratory and Critical Care Medicine*, vol. 170, no. 4, pp. 456–465, 2004.

[17] E. C. Rosenow and A. G. Engel, "Acid maltase deficiency in adults presenting as respiratory failure," *The American Journal of Medicine*, vol. 64, no. 3, pp. 485–491, 1978.

[18] B. Al-Shaikh, W. Kinneer, T. W. Higebontt, H. S. Smith, J. M. Shneerson, and I. Wilkinson, "Motor neuron disease presenting as respiratory failure," *British Medical Journal (Clinical Research Ed.)*, vol. 292, no. 6531, pp. 1325–1326, 1986.

[19] A. E. H. Emery, “The muscular dystrophies,” *Lancet*, vol. 359, no. 9307, pp. 687–695, 2002.

[20] J. D. Finder, "A 2009 perspective on the 2004 American Thoracic Society statement, respiratory care of the patient with Duchenne muscular dystrophy," *Pediatrics*, vol. 123, 4, pp. S239–S241, 2009.

[21] W. D. Arnold, D. Kassar, and J. T. Kissel, “Spinal muscular atrophy: diagnosis and management in a new therapeutic era," *Muscle & Nerve*, vol. 51, no. 2, pp. 157–167, 2015.

[22] A. Modoni, G. Silvestri, M. G. Vita, D. Quaranta, P. A. Tonali, and C. Marra, "Cognitive impairment in myotonic dystrophy type 1 (DM1): a longitudinal follow-up study," *Journal of Neurology*, vol. 255, no. 11, pp. 1737–1742, 2008.

[23] D. Hilton-Jones, “Myotonic dystrophy—forgotten aspects of an often neglected condition," *Current Opinion in Neurology*, vol. 10, no. 5, pp. 399–401, 1997.

[24] C. Roussos and S. Zakynthinos, “Fatigue of the respiratory muscles,” *Intensive Care Medicine*, vol. 22, no. 2, pp. 134–155, 1996.

[25] M. J. Tobin, W. Perez, S. M. Guenther et al., “The pattern of breathing during successful and unsuccessful trials of weaning from mechanical ventilation," *American Review of Respiratory Disease*, vol. 134, no. 6, pp. 1111–1118, 1986.

[26] J. O. Benditt, "Management of pulmonary complications in neuromuscular disease," *Physical Medicine and Rehabilitation Clinics of North America*, vol. 9, no. 1, pp. 167–185, 1998.

[27] M. Eikermann, F. M. Vogt, F. Herbstreit et al., "The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade," *American Journal of Respiratory and Critical Care Medicine*, vol. 175, no. 1, pp. 9–15, 2007.

[28] B. Fauroux and S. Khirani, “Neuromuscular disease and respiratory physiology in children: putting lung function into perspective," *Respir and Critical Care Medicine*, vol. 19, no. 6, pp. 782–791, 2014.

[29] L. T. Mulreany, D. J. Weiner, J. M. McDonough, H. B. Panitch, and J. L. Allen, "Noninvasive measurement of the tension-time index in children with neuromuscular disease," *Journal of Applied Physiology*, vol. 95, no. 3, pp. 931–937, 2003.

[30] F. D. McCool and D. E. Leith, "Pathophysiology of cough," *Clinics in Chest Medicine*, vol. 8, no. 2, pp. 189–195, 1987.

[31] J. M. Poponick, I. Jacobs, G. Supinski, and A. F. DiMarco, “Effect of upper respiratory tract infection in patients with
neuromuscular disease,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 2, pp. 659–664, 1997.
[32] G. A. Gould, M. Gugger, J. Molloy, V. Tsara, C. M. Shapiro, and N. J. Douglas, “Breathing pattern and eye movement density during REM sleep in humans,” American Review of Respiratory Disease, vol. 138, no. 4, pp. 874–877, 1988.
[33] N. J. Douglas, D. P. White, J. V. Weil et al., “Hypoxic ventilatory response decreases during sleep in normal men,” The American Review of Respiratory Disease, vol. 125, no. 3, pp. 286–289, 1982.
[34] N. J. Douglas, D. P. White, J. V. Weil, C. K. Pickett, and C. W. Zwilllich, “Hypercapnic ventilatory response in sleeping adults,” The American Review of Respiratory Disease, vol. 126, no. 5, pp. 758–762, 1982.
[35] V. Malik, D. Smith, and T. Lee-Chiong, “Respiratory physiology during sleep,” Sleep Medicine Clinics, vol. 7, no. 3, pp. 497–505, 2012.
[36] D. W. Hudgel and P. Devadatta, “Decrease in functional residual capacity during sleep in normal humans,” Journal of Applied Physiology, vol. 57, no. 5, pp. 1319–1322, 1984.
[37] E. Tabachnik, N. L. Muller, A. C. Bryan, and H. Levison, “Changes in ventilation and chest wall mechanics during sleep in normal adolescents,” Journal of Applied Physiology, vol. 51, no. 3, pp. 557–564, 1981.
[38] A. Kay, J. Trinder, and Y. Kim, “Progressive changes in airway resistance during sleep,” Journal of Applied Physiology, vol. 81, no. 1, pp. 282–292, 1996.
[39] R. Ragette, U. Mellies, C. Schwake, T. Voit, and H. Teschler, “Patterns and predictors of sleep disordered breathing in primary myopathies,” Thorax, vol. 57, no. 8, pp. 724–728, 2002.
[40] K. Rezania, F. D. Goldenberg, and S. White, “Neuromuscular diseases and acute respiratory failure: diagnosis and management,” Neurologic Clinics, vol. 30, no. 1, pp. 161–185, 2012.
[41] J. M. Shneerson and A. K. Simonds, “Noninvasive ventilation for chest wall and neuromuscular diseases,” European Respiratory Journal, vol. 20, no. 2, pp. 480–487, 2002.
[42] F. Barbé, M. A. Quera-Salva, C. McCann et al., “Sleep-related respiratory disturbances in patients with Duchenne muscular dystrophy,” European Respiratory Journal, vol. 7, no. 8, pp. 1403–1408, 1994.
[43] Y. Khan and J. Z. Heckmatt, “Obstructive apneas in Duchenne muscular dystrophy,” Thorax, vol. 49, no. 2, pp. 157–161, 1994.
[44] P. E. Smith, P. M. Calverley, and R. H. Edwards, “Hypoxemia during sleep in Duchenne muscular dystrophy,” American Review of Respiratory Disease, vol. 137, no. 4, pp. 884–888, 1988.
[45] F. Cirignotta, S. Mondini, M. Zacconi et al., “Sleep-related breathing impairment in myotonic dystrophy,” Journal of Neurology, vol. 235, no. 2, pp. 80–85, 1987.
[46] J. E. White, M. J. Drinnan, A. J. Smithson, C. J. Griffiths, and G. J. Gibson, “Respiratory muscle activity and oxygenation during sleep in patients with muscle weakness,” European Respiratory Journal, vol. 8, no. 5, pp. 807–814, 1995.
[47] U. Mellies, R. Ragette, C. Schwake, M. Baethmann, T. Voit, and H. Teschler, “Sleep-disordered breathing and respiratory failure in acid maltase deficiency,” Neurology, vol. 57, no. 7, pp. 1290–1295, 2001.
[48] C. Santos, A. Braghieri, L. Mazzini, R. Pratesi, L. V. Oliveira, and G. Mora, “Sleep-related breathing disorders in amyotrophic lateral sclerosis,” Monaldi Archives for Chest Disease, vol. 59, no. 2, pp. 160–165, 2003.
[49] K. A. Ferguson, M. J. Strong, D. Ahmad, and C. F. George, “Sleep-disordered breathing in amyotrophic lateral sclerosis,” Chest, vol. 110, no. 3, pp. 664–669, 1996.
[50] M. Labanowski, W. Schmidt-Nowara, and C. Guillemaintault, “Sleep and neuromuscular disease: frequency of sleep-disordered breathing in a neuromuscular disease clinic population,” Neurology, vol. 47, no. 5, pp. 1173–1180, 1996.
[51] J. Lemay, F. Sériès, M. Sénechal, B. Maranda, and F. Maltais, “Unusual respiratory manifestations in two young adults with Duchenne muscular dystrophy,” Canadian Respiratory Journal, vol. 19, no. 1, pp. 37–40, 2012.
[52] A. Sankari, A. T. Bascom, S. Chowdhuri, and M. S. Badr, “Tetraplegia is a risk factor for central sleep apnea,” Journal of Applied Physiology, vol. 116, no. 3, pp. 345–353, 2014.
[53] S. C. Bourke and G. J. Gibson, “Sleep and breathing in neuromuscular disease,” European Respiratory Journal, vol. 19, no. 6, pp. 1194–1201, 2002.
[54] F. Laghi and M. J. Tobin, “Disorders of the respiratory muscles,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 1, pp. 10–48, 2003.
[55] C. Fromageot, F. Lofaso, D. Annane et al., “Supine fall in lung volumes in the assessment of diaphragmatic weakness in neuromuscular diseases,” Archives of Physical Medicine and Rehabilitation, vol. 82, no. 1, pp. 123–128, 2001.
[56] L. S. Aboussouan, “Sleep-disordered breathing in neuromuscular disease,” American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 9, pp. 979–989, 2015.
[57] A. Czapinski, A. A. Yen, and S. H. Appel, “Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 77, no. 3, pp. 390–392, 2006.
[58] E. P. Schmidt, D. B. Drachman, C. M. Wiener, L. Clawson, R. Kimball, and N. Lechtzin, “Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design,” Muscle & Nerve, vol. 33, no. 1, pp. 127–132, 2006.
[59] J. Gayraud, M. Ramonatxo, F. Rivier, V. Humbercllaude, B. Petrof, and S. Matecki, “Ventilatory parameters and maximal respiratory pressure changes with age in Duchenne muscular dystrophy patients,” Pediatric Pulmonology, vol. 45, no. 6, pp. 552–559, 2010.
[60] M. P. Phillips, R. C. Quinlivan, R. H. Edwards, and P. M. Calverley, “Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 12, pp. 2191–2194, 2001.
[61] Y. Ishikawa, T. Miura, Y. Ishikawa et al., “Duchenne muscular dystrophy: survival by cardio-respiratory interventions,” Neuromuscular Diseases, vol. 21, no. 1, pp. 47–51, 2011.
[62] C. Dohna-Schwake, R. Ragette, H. Teschler, T. Voit, and U. Mellies, “Predictors of severe chest infections in pediatric neuromuscular diseases,” Neuromuscular Diseases, vol. 16, no. 5, pp. 325–328, 2006.
[63] R. A. Lyall, N. Donaldson, M. I. Polkey, P. N. Leigh, and J. Moxham, “Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis,” Brain Journal of Neurology, vol. 124, no. 10, pp. 2000–2013, 2001.
[64] C. A. Hukins and D. R. Hillman, “Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy,” American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 1, pp. 166–170, 2000.
[65] S. T. Kuhnik, V. MacBean, S. S. Birring, J. Moxham, G. F. Rafferty, and L. Kalra, “Accuracy of portable devices in measuring peak cough flows,” *Physiological Measurement*, vol. 36, no. 2, pp. 243–257, 2015.

[66] E. K. Plowman, S. A. Watts, R. Robison et al., “Voluntary cough airflow differentiates safe versus unsafe swallowing in amyotrophic lateral sclerosis,” *Dysphagia*, vol. 31, no. 3, pp. 383–390, 2016.

[67] J. R. Bach and L. R. Saporito, “Criteria for extubation and tracheostomy tube removal for patients with ventilatory failure. A different approach to weaning,” *Chest*, vol. 110, no. 6, pp. 1566–1571, 1996.

[68] A. C. Tzeng and J. R. Bach, “Prevention of pulmonary morbidity for patients with neuromuscular disease,” *Chest*, vol. 118, no. 5, pp. 1390–1396, 2000.

[69] J. Sancho, E. Servera, J. Díaz, and J. Marín, “Predictors of ineffective cough during a chest infection in patients with stable amyotrophic lateral sclerosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 175, no. 12, pp. 1266–1271, 2007.

[70] J. R. Bach, Y. Ishikawa, and H. Kim, “Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy,” *Chest*, vol. 112, no. 4, pp. 1024–1028, 1997.

[71] L. J. Boitano, “Management of airway clearance in neuromuscular disease,” *Respiratory Care*, vol. 51, no. 8, pp. 913–922, 2006. Discussion 922-924

[72] S. W. Kang and J. R. Bach, “Maximum insufflation capacity: vital capacity and cough flows in neuromuscular disease,” *American Journal of Physical Medicine & Rehabilitation*, vol. 79, no. 3, pp. 222–227, 2000.

[73] M. I. Polkey, R. A. Lyall, M. Green, P. Nigel Leigh, and J. Moxham, “Expiratory muscle function in amyotrophic lateral sclerosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 158, no. 3, pp. 734–741, 1998.

[74] M. B. Chaudri, C. Liu, R. Hubbard, D. Jefferson, and W. J. Kinneir, “Relationship between supramaximal flow during cough and mortality in motor neurone disease,” *European Respiratory Journal*, vol. 19, no. 3, pp. 434–438, 2002.

[75] Y. Ishikawa and J. R. Bach, “Physical medicine respiratory muscle aids to avert respiratory complications of pediatric chest wall and vertebral deformity and muscle dysfunction,” *European Journal of Physical and Rehabilitation Medicine*, vol. 46, no. 4, pp. 581–597, 2010.

[76] J. R. Bach, K. Mahajan, B. Lipa, L. Saporito, M. Goncalves, and E. Komaroff, “Lung insufflation capacity in neuromuscular disease,” *American Journal of Physical Medicine & Rehabilitation*, vol. 87, no. 9, pp. 720–725, 2008.

[77] S. W. Kang and J. R. Bach, “Maximum insufflation capacity,” *Chest*, vol. 118, no. 1, pp. 61–65, 2000.

[78] J. W. Fitting, “Volitional assessment of respiratory muscle strength,” *Monaldi Archives for Chest Disease*, vol. 77, no. 1, pp. 19–22, 2012.

[79] U. Mellies, R. Ragette, C. Schwake, H. Boehm, T. Voit, and H. Teschner, “Daytime predictors of sleep disordered breathing in children and adolescents with neuromuscular diseases,” *Neuromuscular Diseases*, vol. 13, no. 2, pp. 123–128, 2003.

[80] M. Toussaint, M. Steens, and P. Soudon, “Lung function accurately predicts hypercapnia in patients with Duchenne muscular dystrophy,” *Chest*, vol. 131, no. 2, pp. 368–375, 2007.

[81] A. Hahn, J. R. Bach, A. Delaubier, A. Renardej-Irani, C. Guillou, and Y. Rideau, “Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy,” *Archives of Physical Medicine and Rehabilitation*, vol. 78, no. 1, pp. 1–6, 1997.

[82] R. M. Kravitz, “Airway clearance in Duchenne muscular dystrophy,” *Pediatrics*, vol. 123, 4, pp. S231–S235, 2009.

[83] F. Lofaso, F. Nicot, M. Lejaille et al., “Sniff nasal inspiratory pressure: what is the optimal number of sniffs?,” *European Respiratory Journal*, vol. 27, no. 5, pp. 980–982, 2006.

[84] M. B. Chaudri, C. Liu, L. Watson, D. Jefferson, and W. J. Kinneir, “Sniff nasal inspiratory pressure as a marker of respiratory function in motor neuron disease,” *European Respiratory Journal*, vol. 15, no. 3, pp. 539–542, 2000.

[85] R. K. Morgan, S. McNally, M. Alexander, R. Conroy, O. Hardiman, and R. W. Costello, “Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis,” *American Journal of Respiratory and Critical Care Medicine*, vol. 171, no. 3, pp. 269–274, 2005.

[86] R. Capozzo, V. N. Qua ranta, F. Pellegrini et al., “Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis,” *Journal of Neurology*, vol. 262, no. 3, pp. 593–603, 2015.

[87] V. Nève, J.-M. Cuisset, J.-L. Edmé et al., “Sniff nasal inspiratory pressure in the longitudinal assessment of young Duchenne muscular dystrophy children,” *European Respiratory Journal*, vol. 42, no. 3, pp. 671–680, 2013.

[88] J. Hull, R. Anjaparvan, E. Chan et al., “British Thoracic Society guideline for respiratory management of children with neuromuscular weakness,” *Thorax*, vol. 67, 1pp. i1–i40, 2012.

[89] R. B. Berry, A. Chediak, L. K. Brown et al., “Best clinical practices for the sleep center adjustment of noninvasive positive pressure ventilation (NPPV) in stable chronic alveolar hypoventilation syndromes,” *Journal of Clinical Sleep Medicine*, vol. 6, no. 5, pp. 491–509, 2010.

[90] M. Boentert, H. Prigent, K. Várdi et al., “Practical recommendations for diagnosis and management of respiratory muscle weakness in late-onset Pompe disease,” *International Journal of Molecular Sciences*, vol. 17, no. 10, p. 1735, 2016.

[91] PlumX Metrics, “Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation—a consensus conference report,” *Chest*, vol. 116, no. 2, pp. 521–534, 1999.

[92] V. A. Sansone, C. Gagnon, and Participants of the 207th ENMC Workshop, “207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: management and implications for research, 27–29 June 2014, Naarden, The Netherlands,” *Neuromuscular Diseases*, vol. 25, no. 5, pp. 432–442, 2015.

[93] M. M. Grigg-Damberger, L. K. Wagner, and L. K. Brown, “Sleep hypoventilation in patients with neuromuscular diseases,” *Sleep Medicine Clinics*, vol. 7, no. 4, pp. 667–687, 2012.

[94] J. Nardi, H. Prigent, A. Adala et al., “Nocturnal oximetry and transcutaneous carbon dioxide in home-ventilated neuromuscular patients,” *Respiratory Care*, vol. 57, no. 9, pp. 1425–1430, 2012.

[95] K. A. Bauman, A. Kurili, S. L. Schmidt, G. M. Rodriguez, A. E. Chiodo, and R. G. Sitrin, “Home-based overnight transcutaneous capnography/pulse oximetry for diagnosing nocturnal hypoventilation associated with neuromuscular diseases,” *Archives of Physical Medicine and Rehabilitation*, vol. 94, no. 1, pp. 46–52, 2013.
[96] K. A. Bauman, A. Kurili, H. M. Schotland, G. M. Rodriguez, A. E. Chioco, and R. G. Sitrin, “Simplified approach to diagnosing sleep-disordered breathing and nocturnal hypercapnia in individuals with spinal cord injury,” Archives of Physical Medicine and Rehabilitation, vol. 97, no. 3, pp. 363–371, 2016.

[97] R. B. Berry, R. Budhiraja, D. J. Gottlieb et al., “Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the American Academy of Sleep Medicine,” Journal of Clinical Sleep Medicine, vol. 8, no. 5, pp. 597–619, 2012.

[98] A. Ogna, M.-A. Quera Salva, H. Prigent et al., “Nocturnal hypoventilation in neuromuscular disease: prevalence according to different definitions issued from the literature,” Sleep and Breathing, vol. 20, no. 2, pp. 575–581, 2016.

[99] M. Georges, V. Attali, J. L. Golmard et al., “Reduced survival in patients with ALS with upper airway obstructive events on noninvasive ventilation,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, no. 10, pp. 1045–1050, 2016.

[100] V. N. Quaranta, P. Carratù, M. F. Damiani et al., “The prognostic role of obstructive sleep apnea at the onset of amyotrophic lateral sclerosis,” Neurodegenerative Diseases, vol. 17, no. 1, pp. 14–21, 2017.

[101] Y. Molgat-Seon, L. M. Hannan, P. B. Dominelli et al., “Lung volume recruitment acutely increases respiratory system compliance in individuals with severe respiratory muscle weakness,” ERJ Open Research, vol. 3, no. 1, p. 00135, 2017.

[102] D. R. Hess, “The growing role of noninvasive ventilation in patients requiring prolonged mechanical ventilation,” Respiratory Care, vol. 57, no. 6, pp. 900–918, 2012, Discussion 918–920.

[103] N. S. Hill, “Noninvasive ventilation. Does it work, for whom, and how?,” American Review of Respiratory Disease, vol. 147, no. 4, pp. 1050–1055, 1993.

[104] A. H. Nickol, N. Hart, N. S. Hopkinson, J. Moxham, A. Simonds, and M. I. Polkey, “Mechanisms of improvement of respiratory failure in patients with restrictive thoracic disease treated with noninvasive ventilation,” Thorax, vol. 60, no. 9, pp. 754–760, 2005.

[105] EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, P. M. Andersen, S. Abrahams et al., “EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (ALS)—revised report of an EFNS task force,” European Journal of Neurology, vol. 19, no. 3, pp. 360–375, 2012.

[106] D. A. McKim, J. Road, M. Avendano et al., “Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline,” Canadian Respiratory Journal, vol. 18, no. 4, pp. 197–215, 2011.

[107] “International consensus conferences in intensive care medicine: noninvasive positive pressure ventilation in acute respiratory failure,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 1, pp. 283–291, 2001.

[108] M. Agrafiotis, K. Nikolau, D. Siopi, and D. Chloros, “Open-circuit mouthpiece ventilation: indications, evidence and practicalities,” Noninvasive Ventilation in Medicine—Recent Updates, IntechOpen, 2018.

[109] J. R. Bach, A. S. Alba, and L. R. Saporito, “Intermittent positive pressure ventilation via the mouth as an alternative to tracheostomy for 257 ventilator users,” Chest, vol. 103, no. 1, pp. 174–182, 1993.

[110] J. R. Bach, M. R. Gonçalves, I. Hamdani, and J. C. Winck, “Exubation of patients with neuromuscular weakness: a new management paradigm,” Chest, vol. 137, no. 5, pp. 1033–1039, 2010.

[111] S. C. Bourke, M. Tomlinson, T. L. Williams, R. E. Bullock, P. J. Shaw, and G. J. Gibson, “Effects of noninvasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial,” The Lancet Neurology, vol. 5, no. 2, pp. 140–147, 2006.

[112] D. J. Berlowitz, M. E. Howard, J. F. Fiore et al., “Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, no. 3, pp. 280–286, 2016.

[113] A. K. Simonds, F. Muntoni, S. Heather, and S. Fielding, “Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy,” Thorax, vol. 53, no. 11, pp. 949–952, 1998.

[114] J. Jeppesen, A. Green, B. F. Steffensen, and J. Rahbek, “The Duchenne muscular dystrophy population in Denmark, 1977–2001: prevalence, incidence and survival in relation to the introduction of ventilator use,” Neuromuscular Diseases, vol. 13, no. 10, pp. 804–812, 2003.

[115] B. Vrijens, B. Buyse, C. Belge et al., “Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study,” Journal of Clinical Sleep Medicine, vol. 11, no. 5, pp. 559–566, 2015.

[116] M. Boentert, I. Brenscheidt, C. Glatz, and P. Young, “Effects of noninvasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 82, no. 9, pp. 2073–2082, 2015.

[117] U. Mellies, C. Dohna-Schwake, F. Stehling, and T. Voit, “Sleep disordered breathing in spin muscular atrophy,” Neuromuscular Diseases, vol. 14, no. 12, pp. 797–803, 2004.

[118] A. Petrone, M. Pavone, M. B. C. Testa, F. Petreschi, E. Bertini, and R. Cutrera, “Noninvasive ventilation in children with spinal muscular atrophy types 1 and 2,” American Journal of Physical Medicine & Rehabilitation, vol. 86, no. 3, pp. 216–221, 2007.

[119] C. Guilleminault, P. Philip, and A. Robinson, “Sleep and neuromuscular disease: bilevel positive airway pressure by nasal mask as a treatment for sleep disordered breathing in patients with neuromuscular disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 65, no. 2, pp. 225–232, 1998.

[120] J. R. Bach, L. R. Saporito, H. R. Shah, and D. Singue, “Decanulation of patients with severe respiratory muscle insufficiency: efficacy of mechanical insufflation-exsufflation,” Journal of Rehabilitation Medicine, vol. 46, no. 10, pp. 1037–1041, 2014.

[121] J. R. Bach, M. R. Gonçalves, A. Hon et al., “Changing trends in the management of end-stage neuromuscular respiratory muscle failure: recommendations of an international consensus,” American Journal of Physical Medicine & Rehabilitation, vol. 92, no. 3, pp. 267–277, 2013.

[122] J. R. Bach, A. S. Alba, G. Bohatiuk, L. Saporito, and M. Lee, “Mouth intermittent positive pressure ventilation in the management of postpolio respiratory insufficiency,” Chest, vol. 91, no. 6, pp. 859–864, 1987.

[123] M. Toussaint, M. Steens, G. Wastes, and P. Soudon, “Diurnal ventilation via mouthpiece: survival in end-stage Duchenne patients,” European Respiratory Journal, vol. 28, no. 3, pp. 549–555, 2006.
[124] J. R. Bach, V. Niranjan, and B. Weaver, “Spinal muscular atrophy type 1: a noninvasive respiratory management approach,” Chest, vol. 117, no. 4, pp. 1100–1105, 2000.

[125] J. R. Bach, “POINT: Is noninvasive ventilation always the most appropriate manner of long-term ventilation for infants with spinal muscular atrophy type 1? Yes, almost always,” Chest, vol. 151, no. 5, pp. 962–965, 2017.

[126] M. Toussaint, M. Chatwin, J. Gonzales, D. J. Berlowitz, and ENMC Respiratory Therapy Consortium, “228th ENMC International Workshop: Airway clearance techniques in neuromuscular diseases Naarden, The Netherlands, 3–5 March, 2017,” Neuromuscular Diseases, vol. 28, no. 3, pp. 289–298, 2018.

[127] M. Chatwin, M. Toussaint, M. R. Gonçalves et al., “Airway clearance techniques in neuromuscular diseases: a state of the art review,” Respiratory Medicine, vol. 136, pp. 98–110, 2018.

[128] S. L. Katz, N. Barrowman, A. Monsour, S. Su, L. Hoey, and D. McKim, “Long-term effects of lung volume recruitment on maximal inspiratory capacity and vital capacity in Duchenne muscular dystrophy,” Annals of the American Thoracic Society, vol. 13, no. 2, pp. 217–222, 2016.

[129] M. Chiou, J. R. Bach, L. Jethani, and M. E. Gallagher, “Active lung volume recruitment to preserve vital capacity in Duchenne muscular dystrophy,” Journal of Rehabilitation Medicine, vol. 49, no. 1, pp. 49–53, 2017.

[130] D. A. McKim, S. L. Katz, N. Barrowman, A. Ni, and C. LeBlanc, “Lung volume recruitment slows pulmonary function decline in Duchenne muscular dystrophy,” Archives of Physical Medicine and Rehabilitation, vol. 93, no. 7, pp. 1117–1122, 2012.

[131] F. Stehling, A. Bouikidis, U. Schara, and U. Mellies, “Mechanical insufflation/exsufflation improves vital capacity in neuromuscular diseases,” Chronic Respiratory Disease, vol. 12, no. 1, pp. 31–35, 2015.

[132] F. Racca, L. Del Sorbo, T. Mongini, A. Vianello, and V. M. Ranieri, “Respiratory management of acute respiratory failure in neuromuscular diseases,” Minerva Anestesiologica, vol. 76, no. 1, pp. 51–62, 2010.

[133] A. C. Davidson, S. Banham, M. Elliott et al., “BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults,” Thorax, vol. 71, no. Suppl 2, pp. 11–135, 2016.

[134] A. K. Simonds, “Ventilator support in children with neuromuscular diseases,” Caring for the Ventilator Dependent Child: A Clinical Guide, L. M. Sterni and J. L. Carroll, Eds., pp. 283–298, Springer, New York, NY, 2016.

[135] T.-H. Chen, J.-H. Hsu, J.-R. Wu et al., “Combined noninvasive ventilation and mechanical in-exsufflator in the treatment of pediatric acute neuromuscular respiratory failure,” Pediatric Pulmonology, vol. 49, no. 6, pp. 589–596, 2014.